Kidney Amyloidosis in Cats: Symptoms, Causes & Emerging Treatments

What Is Kidney Amyloidosis in Cats?

Kidney amyloidosis (more precisely called amyloid nephropathy) is a serious, progressive disease in which misfolded proteins build up inside the kidneys, slowly destroying their ability to filter waste. It is uncommon in the general cat population but is a leading cause of secondary kidney failure in certain breeds and in cats with long-standing inflammation.

Amyloidosis is a broad term for conditions in which insoluble protein fragments called amyloid fibrils are deposited outside cells in various tissues, disrupting normal architecture and organ function ^[1]. When these deposits form primarily in the kidneys, the resulting disease is called amyloid nephropathy, and the damage typically evolves into chronic kidney disease (CKD), a permanent, progressive loss of kidney function ^[2].

In cats, the most common form is AA amyloidosis, also called reactive or secondary amyloidosis. It develops from serum amyloid A (SAA), an acute-phase protein that the liver produces in large amounts during prolonged inflammation ^[1]. Over time, fragments of SAA misfold into rigid, sheet-like fibrils that wedge themselves between cells and cannot be cleared by the body. A second form, AL amyloidosis, arises from immunoglobulin light chains (antibody building blocks) produced by plasma cell tumors such as multiple myeloma, but it is exceedingly rare in cats ^[2].

Amyloid nephropathy shows up in three clinical patterns in cats:

• Familial or hereditary AA amyloidosis, well-documented in Abyssinian, Siamese, and Oriental Shorthair cats, but with a breed-specific organ distribution: Abyssinian cats typically develop primarily renal (kidney) deposits, while Siamese cats tend to develop predominantly hepatic (liver) deposits; Oriental Shorthair cats share this familial predisposition ^{[1, 3]}.
• Secondary AA amyloidosis, triggered by chronic inflammatory or infectious diseases such as feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), and feline infectious peritonitis (FIP) ^{[1, 4]}.
• Idiopathic amyloidosis, in which no underlying trigger can be identified. The proportion of truly idiopathic cases remains poorly defined.

A striking recent finding is that in some shelter cat populations with high overall inflammation, approximately 79% of cats with AA amyloidosis have deposits in the kidneys, suggesting chronic inflammation is a powerful permissive factor for amyloid formation in this species ^[1].

Symptoms and Early Signs of Kidney Amyloidosis

The earliest sign of kidney amyloidosis is often no sign at all: cats in the beginning stages can look completely normal, which is why the disease is usually diagnosed late. Once kidney function slips, the clinical picture is very similar to other forms of chronic kidney disease.

In early IRIS stages 1–2 (the International Renal Interest Society's standard staging system, based on blood creatinine and SDMA levels), cats may show only subtle changes such as gradual weight loss and a dull or unkempt hair coat ^[3]. As the kidneys lose their ability to concentrate urine, the classic signs of increased thirst and increased urination (polydipsia and polyuria, often abbreviated PU/PD) appear ^{[3, 5]}.

With progressive azotemia (buildup of nitrogen waste products in the blood because failing kidneys cannot filter them out), gastrointestinal signs emerge: reduced appetite, nausea, vomiting, and sometimes diarrhea ^[5]. Owners may also notice general signs of illness including lethargy, weakness, and reduced grooming ^{[3, 5]}.

On physical examination, veterinarians often find:

• Dehydration (sunken eyes, tacky gums, skin that stays tented when pinched)
• Pale gums from nonregenerative anemia (anemia the bone marrow cannot replace)
• Gingivitis or oral inflammation
• Small, firm, irregular kidneys that feel bumpy on abdominal palpation ^[3]

In cats with heavy glomerular involvement (damage to the kidney's filtering units), severe proteinuria (excess protein in the urine) can lead to nephrotic syndrome, a constellation of signs caused by massive protein loss: fluid accumulation in the belly (ascites), in the chest (pleural effusion), and under the skin (peripheral edema) ^[5].

The age of onset depends on the form:

• Familial cases in Abyssinians typically present between 1 and 5 years of age ^[3]; Siamese and Oriental Shorthairs may show signs as early as 1–4 years, sometimes with liver involvement ^{[5, 3]}.
• Secondary and idiopathic forms are usually diagnosed in older cats, with risk climbing steadily after 7 years ^[5].

Causes and Risk Factors for Kidney Amyloidosis

The three main drivers of feline kidney amyloidosis are inherited breed predisposition, chronic inflammation or infection, and, in a meaningful subset of cases, no identifiable cause at all. Knowing which category your cat falls into guides both treatment and prevention.

Familial AA amyloidosis has been reported in Abyssinian, Siamese, and Oriental Shorthair cats. Affected cats inherit a tendency to misfold their SAA protein, although the exact genetic mutations and mode of inheritance remain incompletely defined ^{[1, 3]}. Distinct amino acid substitutions in the SAA protein have been described in Siamese versus Abyssinian cats, which may explain why Siamese cats tend to develop prominent liver deposits while Abyssinians deposit primarily in the kidneys ^[3].

Secondary (reactive) AA amyloidosis develops when the liver is forced to produce SAA at chronically high levels. The most important triggers in cats include:

• FIV (feline immunodeficiency virus), naturally infected cats have a markedly higher prevalence of amyloid deposits, confirming FIV's role ^[4].
• FeLV (feline leukemia virus) ^[4]
• FIP (feline infectious peritonitis) ^[1]
• Chronic inflammatory conditions such as severe oral inflammation (stomatitis) and inflammatory bowel disease

Some of these associations are based on known AA pathophysiology and clinical observation rather than large-scale prevalence studies specific to the kidney form.

AL amyloidosis is exceptionally rare in cats and is associated with plasma cell disorders (plasma cell tumors and multiple myeloma) ^[2].

Finally, idiopathic cases occur when a thorough diagnostic workup finds no underlying inflammatory, infectious, or neoplastic trigger. How common this is remains unknown.

Key risk factors at a glance:

• Breed: Abyssinian, Siamese, and Oriental Shorthair for the familial form.
• Age: younger for familial cases; older than 7 years for secondary or idiopathic disease.
• Environment: shelter cats and cats with chronic infectious or inflammatory disease carry elevated risk ^{[5, 1]}.

How Kidney Amyloidosis Is Diagnosed in Cats

The diagnosis is suspected from signalment (the cat's breed, age, and history), clinical signs, and lab abnormalities, and is only confirmed by looking at kidney tissue under a microscope. A high index of suspicion allows owners and veterinarians to act quickly, because early supportive care can meaningfully slow progression ^[5].

Routine bloodwork typically reveals:

• Azotemia (elevated blood urea nitrogen and creatinine, signs of waste buildup)
• Hyperphosphatemia (high blood phosphorus)
• Metabolic acidosis
• Nonregenerative anemia ^[3]

Urinalysis shows isosthenuria (urine that is neither more nor less concentrated than plasma, a sign of failing kidney concentration ability) and variable proteinuria. The urine protein-to-creatinine ratio (UPC) is a standardized measure of protein loss; it is often significantly elevated in affected cats, but because many other kidney diseases cause proteinuria too, the UPC alone cannot distinguish amyloidosis from other problems ^{[1, 3]}.

Abdominal ultrasound often reveals small, irregular kidneys with poor corticomedullary distinction, meaning the line between the outer cortex and inner medulla becomes blurred, but these findings also are not specific.

The definitive diagnosis requires histopathology, actual examination of kidney tissue. Pathologists stain the sample with Congo red dye, and under polarized light the amyloid deposits glow in a signature apple-green color ^[3]. A surgical wedge biopsy containing both cortex and medulla is preferred, especially in Abyssinians where deposits concentrate in the medulla ^[3]. Percutaneous needle biopsies (cores taken through a needle poked through the skin) can miss the diagnosis when deposits are focal or confined to the medulla.

Immunohistochemistry or immunofluorescence using anti-AA antibodies confirms the amyloid type, distinguishing AA amyloidosis from other forms ^[1].

For owners who cannot or do not want to pursue a biopsy, a less invasive urine test called the urine amyloid A-to-creatinine ratio (UAAC) is showing real promise: in shelter cats with renal AA amyloidosis, a markedly elevated UAAC was consistently observed and points toward the diagnosis even when biopsy is not feasible ^[1].

Advanced research tools such as liquid chromatography-mass spectrometry (LC-MS), a technique that catalogs thousands of proteins at once, can identify candidate biomarkers like apolipoprotein C-III (a lipid-transport protein) that correlate with AA amyloidosis, but these methods remain research-only for now ^[1].

Stages and Forms of Kidney Amyloidosis

Kidney amyloidosis is described in two parallel ways: by the type of amyloid protein deposited and by the international CKD (IRIS) stage at diagnosis. Both classifications help your veterinarian plan treatment and give you a realistic prognosis.

By amyloid type:

• AA (reactive/secondary), far and away the most common in cats ^[1]
• AL (primary), exceedingly rare, associated with plasma cell disorders ^[2]

By underlying cause:

• Familial/hereditary (Abyssinian, Siamese, Oriental Shorthair) ^{[1, 3]}
• Secondary to chronic inflammation or infection ^[1]
• Idiopathic ^[1]

By IRIS CKD stage, applied the same way as for any other CKD:

• Stage 1: non-azotemic (normal blood creatinine/SDMA), but other signs of kidney damage may be present
• Stage 2: mild azotemia
• Stage 3: moderate azotemia
• Stage 4: severe azotemia/uremia ^[1]

What this means for your cat: A cat diagnosed at IRIS Stage 1 or 2 typically has months to a few years of stable quality of life with intensive management, while a cat diagnosed at Stage 3 or 4 often deteriorates within weeks to months. Early diagnosis, especially in predisposed breeds and shelter cats, buys meaningful time.

Histologically, the distribution of deposits also varies:

• In shelter cats with secondary AA amyloidosis, fibrils are typically found in both cortex and medulla, and in glomeruli, tubulointerstitium (the functional tissue around the tubules), and blood vessels ^[1].
• In familial Abyssinian cats, deposits cluster predominantly in the medulla ^{[1, 3]}.
• Glomerulosclerosis (scarring of the filtering units) and interstitial fibrosis (scarring between tubules) are common secondary lesions ^[1].

Veterinary pathologists can assign a semiquantitative amyloid burden score (for example, score 1 = mild, score 2 = marked). Higher scores correlate with multi-organ involvement (liver and spleen) and more advanced renal damage ^[1].

Treatment Options for Cats With Kidney Amyloidosis

There is no medication that dissolves amyloid fibrils or halts the disease outright, so treatment is centered on supportive care that mirrors chronic kidney disease management. The goal is to slow progression, control complications, and keep your cat eating, drinking, and comfortable for as long as possible.

Stabilizing uremic crises. Cats presenting with severe dehydration or uremic signs often need hospitalization with intravenous (IV) fluids to flush accumulated wastes and correct electrolyte imbalances ^{[2, 5]}. Once stable, many cats can be transitioned to subcutaneous (under-the-skin) fluids at home.

Renal therapeutic diet. A kidney-friendly diet for cats should provide:

• High-quality (high biological value) protein in moderate restriction, enough to preserve muscle but not so much that it overwhelms the kidneys ^[6]
• Phosphorus restriction to slow kidney damage ^[6]
• Increased omega-3 fatty acids
• Added water-soluble B and C vitamins, which are easily lost in the dilute urine of kidney patients ^[6]

Phosphate binders. When diet alone cannot control blood phosphorus, intestinal phosphate binders such as lanthanum carbonate can be added to meals .

Blood pressure and proteinuria control. Many cats with kidney amyloidosis develop systemic hypertension. Antihypertensives such as amlodipine (a calcium channel blocker) or telmisartan (an angiotensin receptor blocker) are commonly used to lower blood pressure and reduce glomerular protein loss ^{[2, 5]}.

Antithrombotic medications. Cats with severe protein-losing nephropathy may be at elevated risk of blood clots forming in the heart or major arteries, similar to humans with kidney disease. Some veterinarians prescribe clopidogrel or low-dose aspirin for these cases, although controlled studies proving benefit in feline amyloid nephropathy do not yet exist.

Treating anemia. As the kidneys fail, production of erythropoietin (the hormone that tells the bone marrow to make red blood cells) falls. This can be supplemented with recombinant erythropoietin or its longer-acting cousin darbepoetin ^[6].

Treating the underlying disease. If an inflammatory or infectious cause (chronic infection, stomatitis, IBD, retroviral disease) is identified, managing it may reduce ongoing SAA production and slow further amyloid deposition ^[5].

Daily supportive medications common in the care plan of an amyloidosis cat include:

• Antiemetics such as maropitant to control nausea
• Appetite stimulants such as mirtazapine (which also has anti-nausea effects) to keep cats eating ^[6]
• Potassium supplementation if blood potassium is low ^[3]
• At-home subcutaneous fluids to maintain hydration ^[6]

Scheduled monitoring every 1–3 months, typically a renal blood panel, electrolyte check, blood pressure reading, urine protein measurement, and a weight check, lets your veterinarian adjust the plan as the disease evolves ^[5].

New and Emerging Treatments for Feline Kidney Amyloidosis

No disease-modifying therapy is approved yet for feline kidney amyloidosis, but several promising research avenues are in progress. Most remain experimental or extrapolated from human medicine.

Antioxidant strategies. Cats with renal AA amyloidosis excrete elevated levels of oxidative stress markers, including glutathione peroxidase, selenoprotein P, and selenoprotein M, in their urine ^[1]. This finding suggests antioxidant therapy may be worth evaluating, although controlled trials in cats are lacking.

Colchicine is used in human medicine to slow AA amyloidosis and has also been used in cats with familial AA amyloidosis (notably Abyssinian and Siamese/Oriental Shorthair lines), with reports describing its clinical use in affected cats and as prophylaxis in related breeding cats. However, its narrow therapeutic window and documented toxicity in cats (e.g., gastrointestinal signs, potential bone marrow effects) make its use controversial, and it should only be considered with careful monitoring and informed client consent.

Eprodisate and other small-molecule anti-fibrillogenic drugs (medicines designed to keep amyloid proteins from clumping into fibrils) are approved for human AA amyloidosis in some countries but have not been studied in cats.

Interleukin-1 inhibitors and other biologics that suppress SAA production are theoretically attractive for slowing AA amyloid deposition, but no feline data exist.

Targeting serum amyloid P component (SAP), a protein that coats and stabilizes amyloid deposits, has shown promise in experimental animal models by destabilizing existing plaques and allowing the body to clear them. This remains an experimental strategy with no feline data.

Urine proteomic analyses in cats with renal AA amyloidosis have identified a network of overexpressed proteins involved in oxidative stress, lipid transport, and the complement and coagulation cascades, providing a roadmap of where future drug development might focus ^[1].

Life Expectancy and Long-Term Prognosis

Prognosis is guarded to poor: many cats survive less than a year after diagnosis, although outcomes vary significantly with how early the disease is caught and how aggressively it is managed.

Median survival time after a diagnosis of kidney amyloidosis is often less than 12 months, particularly once azotemia and nephrotic syndrome are established ^{[2, 5]}.

IRIS stage at diagnosis is the single most useful prognostic marker. Cats identified at Stages 1 and 2 often remain stable for months to a few years with intensive management, while cats diagnosed at Stages 3 and 4 tend to deteriorate rapidly ^{[1, 3]}.

Breed matters. Among Abyssinians, some cats with mild medullary deposits may live to advanced age without ever showing clinical signs, silently transmitting the trait within breeding lines; others progress to end-stage kidney failure within a year ^[3].

Nephrotic syndrome, severe proteinuria with fluid accumulation in the abdomen or chest, and accompanying thromboembolic complications (dangerous blood clots, such as the well-known "saddle thrombus" that can lodge in the arteries supplying the hind legs) carry a significantly worse outlook .

Multi-organ amyloid involvement, such as concurrent liver or spleen deposits, is a marker of advanced systemic disease and indicates a shorter expected survival time ^[1].

A positive response to supportive care, combined with effective management of any treatable underlying inflammatory condition, can modestly extend survival and substantially improve day-to-day quality of life ^[5].

Living With and Managing a Cat With Kidney Amyloidosis

Daily life with a kidney amyloidosis cat is built around consistency: medications on schedule, a renal diet, fluids if prescribed, and close observation for subtle changes.

A structured home routine typically involves:

• Prescription renal diet, transitioned gradually over several weeks by mixing it with the previous food, warming canned food slightly, and adding flavor enhancers such as low-sodium clam juice if needed ^[6]
• Daily oral medications (phosphate binders, blood pressure drugs, anti-nausea drugs, appetite stimulants)
• Subcutaneous fluids administered under the skin, typically every one to three days, as directed by your vet
• Appetite, body weight, water intake, urine output, vomiting, and breathing effort tracked at home so the care team catches problems early ^[5]

Cats with kidney amyloidosis have very little functional reserve, so it is important to:

• Avoid nephrotoxic medications (drugs that directly damage the kidneys) such as non-steroidal anti-inflammatory drugs (NSAIDs) unless specifically prescribed
• Stay current on dental cleanings and treat infections promptly
• Minimize physiological stress (board only when necessary, maintain stable routines)

Veterinary rechecks every 1–3 months, including a renal panel, blood pressure measurement, urinalysis, and UPC or UAAC monitoring, are essential to keeping the plan tuned to your cat's current stage ^[5].

For families with breeding cats, affected individuals and their close relatives should be removed from breeding programs to reduce the genetic burden of familial amyloidosis ^[2].

Because the long-term outlook is uncertain, having early, open conversations with your veterinarian about end-of-life care, including hospice or palliative care, is part of responsible management and ensures your cat's comfort comes first when quality of life declines.

Complications, Final Stages, and End-of-Life Care

As kidney amyloidosis advances, complications accumulate and ultimately define the final weeks of life. Knowing what to expect helps owners prepare and advocate for their cat.

Common complications include uremic crisis (sudden, severe kidney failure with vomiting, lethargy, and anorexia), worsening hyperphosphatemia, progressive anemia, and metabolic acidosis (an acid buildup in the blood) ^[3].

Cats with heavy glomerular amyloid deposits frequently develop nephrotic syndrome, leading to ascites, pleural effusion, and peripheral edema. Urine proteomics has revealed heightened excretion of coagulation-related proteins, hinting at a hypercoagulable (pro-clotting) state that may predispose these cats to aortic or other thromboembolic events ^[1].

Multi-organ amyloid involvement is another serious complication:

• Hepatic (liver) involvement can make the liver fragile and prone to spontaneous rupture
• Splenic (spleen) involvement is common but often subclinical ^[1]

In the terminal stages, cats may show profound weakness, intractable vomiting, low body temperature, oral uremic ulcers (painful sores in the mouth from waste buildup), halitosis (a characteristic ammonia-like breath odor), disorientation, stupor, and ultimately coma ^[6].

End-of-life care focuses on comfort:

• Effective pain management
• Antiemetics to control nausea
• Gentle subcutaneous hydration when helpful
• Offering food only if the cat chooses to eat (forced feeding is rarely appropriate)
• A quiet, low-stress environment

Tools such as the Feline Quality of Life Scale (a questionnaire that scores eating, drinking, hygiene, happiness, mobility, and other factors) help families and veterinarians decide when humane euthanasia is the kindest choice.

Providing emotional support, including referrals to pet loss support hotlines and grief resources, is an essential part of comprehensive end-of-life care for both the cat and the family.

Similar Conditions That Can Look Like Kidney Amyloidosis

Many protein-losing or chronically progressive kidney diseases mimic renal amyloidosis, and telling them apart is essential because treatments and prognoses differ. Your veterinarian will use a combination of bloodwork, urinalysis, imaging, and often biopsy to narrow the list.

• Glomerulonephritis (inflammation of the kidney's filtering units, most often caused by immune complex deposition, where antibodies mistakenly stick to kidney structures) is the most common mimic. It also causes proteinuria and azotemia, but biopsy shows immune complex deposits without amyloid ^[3].
• Chronic pyelonephritis (smoldering bacterial infection of the kidney) can produce small, irregular kidneys and progressive azotemia that mimic amyloidosis. Urine culture and abdominal ultrasound help distinguish it by revealing active infection and characteristic imaging features ^{[6, 3]}.
• Polycystic kidney disease (PKD), common in Persian and related breeds, produces enlarged, cystic kidneys on ultrasound, the opposite of the small, irregular kidneys typical of amyloidosis ^[3].
• Renal lymphoma (cancer of lymphocytes in the kidney) usually causes renomegaly (kidney enlargement), and diagnosis can be made with a fine-needle aspirate and cytology ^[3].
• Non-amyloid tubulointerstitial nephritis/fibrosis from other causes is differentiated only on biopsy with Congo red staining and immunohistochemistry ^[1].

What raises strong suspicion for amyloidosis without a biopsy? A disproportionately elevated UAAC ratio in a predisposed breed or shelter cat with proteinuria, combined with small irregular kidneys, is currently the best non-invasive clue ^[1].

What We Still Don't Know: Gaps and Current Research

Despite major recent progress, several fundamental questions about feline kidney amyloidosis remain unanswered, and these gaps shape the direction of current research.

• The exact pathogenesis of amyloid-induced kidney damage in cats is still not fully understood; it is not clear how fibrils trigger glomerulosclerosis and fibrosis ^[1].
• In familial AA amyloidosis of Abyssinians, Siamese, and Oriental Shorthairs, the precise genetic mutations and inheritance patterns have not been fully identified, which limits the development of predictive genetic tests and breeding strategies ^{[1, 3]}.
• Validated non-invasive diagnostic criteria based on the UAAC ratio and urine proteomics are needed to reduce the dependence on kidney biopsy, which is invasive and carries procedural risk ^[1].
• The clinical significance of urinary biomarkers related to oxidative stress, complement activation, and coagulation (such as apolipoprotein C-III) still requires prospective studies to confirm their diagnostic and prognostic value ^[1].
• It is not known whether anti-inflammatory or immunosuppressive treatments can reduce SAA production enough to prevent or delay renal amyloid deposition in at-risk cats.
• No controlled clinical trials of antioxidant therapy or anti-fibrillogenic drugs (such as colchicine or eprodisate) exist in cats, so safety and efficacy in this species remain unexplored ^[1].
• Long-term outcome data stratified by IRIS stage, amyloid burden score, and specific treatment protocols are scarce, limiting precise prognostic counseling.

❓ Frequently Asked Questions

Research document (citation source reference)

The peer-reviewed source literature that informed this article addresses feline AA amyloidosis from several angles. In humans, nonfamilial AA amyloidosis occurs as a sequela of chronic inflammatory diseases, leading to proteinuria and end-stage renal failure; in cats, the same reactive pathway is implicated. In a previous study of a cat shelter with high prevalence of AA amyloidosis, a score derived from abnormal laboratory variables was used to assess disease severity; cats with AA amyloidosis scored higher than those without, suggesting that inflammatory diseases, as in humans, play a permissive role in amyloid fibril deposition. Furthermore, approximately 79% of shelter cats with AA amyloidosis had renal amyloid deposits, and proteinuria or azotemia was common in this group. Renal AA amyloidosis in cats is generally suspected in cases of severe proteinuria, but definitive diagnosis requires tissue histopathology and is rarely made antemortem; in Abyssinian cats with familial AA amyloidosis, SAA concentration is increased, but the wide overlap between affected and nonaffected animals prevents its use as a disease biomarker. The diagnosis of amyloidosis requires proper pathologic evaluation with Congo red staining of an adequate biopsy specimen; a surgical wedge containing both cortical and medullary tissue is more likely to yield a definitive diagnosis than a percutaneous needle biopsy because of the prominent medullary distribution of renal amyloid deposits in the Abyssinian cat, although even a conscientious biopsy effort can return negative results. In a study of Siamese cats with familial amyloidosis and severe hepatic involvement, two amino acid substitutions were identified when comparing the amyloid A protein sequence to that reported for Abyssinian cats with familial amyloidosis; these sequence differences potentially explain the different tissue tropisms (renal in Abyssinian cats versus hepatic in Siamese cats). Approximately two-thirds of shelter cats with renal AA amyloidosis show fibril deposition in both the cortex and medulla, whereas in Abyssinian cats with familial AA amyloidosis deposits are predominantly observed in the medulla.